322 results
8-K
EX-99.1
DMKPQ
DMK Pharmaceuticals Corp
14 Nov 23
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
3:57pm
in compensation and employment separation expenses of approximately $1.1 million.
Research and development (R&D) expense for the third quarter of 2023 … ended September 30, 2023 of $6.5 million for DMK’s in-process research and development acquired in the merger.
Cash and cash equivalents
8-K
EX-99.1
DMKPQ
DMK Pharmaceuticals Corp
21 Aug 23
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
with the DMK merger.
Research and development (R&D) expense for the second quarter of 2023 was $0.4 million compared to $3.2 million in the second quarter … was primarily attributable to a charge of $6.5 million for DMK’s in-process research and development acquired in the merger. Net loss for the six
424B4
DMKPQ
DMK Pharmaceuticals Corp
3 Aug 23
Prospectus supplement with pricing info
4:55pm
revenues and profitability;
our expectations regarding future growth;
our expectations concerning future product research, development, clinical trial … this offering for working capital and general corporate purposes, which may include, without limitation, expenditures relating to research, development
FWP
fezlwnlvfu3ry6xv2thb
27 Jul 23
Free writing prospectus
6:08am
8-K/A
EX-99.2
58ko5v78 ky8e1
15 Jun 23
Report of Independent Registered Public Accounting Firm
6:21pm
8-K/A
EX-99.1
tvo8h
15 Jun 23
Report of Independent Registered Public Accounting Firm
6:21pm
8-K/A
EX-99.3
rvpvte29guxww2ya
15 Jun 23
Report of Independent Registered Public Accounting Firm
6:21pm
8-K
EX-99.1
0vqnt
15 May 23
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:56pm
DEFM14A
x726x8t7q4yn5pvg
13 Apr 23
Proxy related to merger
4:52pm
8-K
EX-99.1
izvkj
14 Nov 22
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:27pm
424B5
rvestc7 119csid2oafw
23 Sep 22
Prospectus supplement for primary offering
5:05pm
8-K
EX-99.1
cq81t7hyrrafx kvlrp
10 Aug 22
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:09pm